🇺🇸 FDA
Pipeline program

ALN-AAT02

ALN-AAT02-001

Phase 2 small_molecule terminated

Quick answer

ALN-AAT02 for ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ALNYLAM PHARMACEUTICALS, INC.
Indication
ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials